Table 1. Demographic data for paediatric FN episodes.
| Median age, years (IQR) | 5.9 (3.5–10.3) |
| Male sex, n (%) | 327 (50.3) |
| Haematological malignancy, n (%) | 412 (63.4) |
| ALL, n | 332 |
| Lymphoma, n | 49 |
| AML, n | 11 |
| Other haem malig., n | 20 |
| Solid tumour, n (%) | 238 (36.6) |
| Sarcoma, n | 112 |
| Brain tumour, n | 55 |
| Neuroblastoma, n | 35 |
| Other solid tumour, n | 36 |
| Relapse/refractory disease, n (%) | 52 (8) |
| Leukaemia/lymphoma, n | 29 |
| Solid tumour, n | 23 |
| Prior HSCT | |
| Allogeneic, n (%) | 8 (1.2) |
| Autologous, n (%) | 15 (2.3) |
| Central venous access device in situ, n (%) | 620 (95) |
| Implanted port, n | 435 |
| Tunnelled external catheter, n | 172 |
| PICC, n | 13 |
| PJP prophylaxis, n (%) | 516 (79.4) |
| Co-trimoxazole, n | 508 |
| Other, n | 6 |
| Fungal prophylaxis, n (%) | 88 (13.5) |
| Yeast-active (fluconazole), n | 64 |
| Mould-active (itra/vori/posaconazole), n | 24 |
| Viral prophylaxis, n (%) | 41 (6.3) |
| HSV/VZV (acyclovir), n | 41 |
| Antibacterial prophylaxis, n (%) | 0 |
| β-Lactam allergy, n (%) | 32 (4.9) |
| Non life-threatening, n | 25 |
| Life-threatening, n | 2 |
| Unknown type, n | 5 |
Abbreviations: ALL=acute lymphoblastic leukaemia; AML=acute myeloid leukaemia; FN=fever and neutropenia; haem malig.=haematological malignancy; HSCT=haematopoietic stem cell transplant; HSV=herpes simplex virus; IQR=interquartile range; PICC=peripherally inserted central catheter; PJP=Pneumocystis jirovecii pneumonia; VZV=varicella zoster virus.